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Positive-feedback loopCaspase-8 (CASP8) is a cysteine protease that plays a pivotal role in the extrinsic apoptotic signaling pathway
via death receptors. The kinetics, dynamics, and selectivity with which the pathway transmits apoptotic sig-
nals to downstream molecules upon CASP8 activation are not fully understood. We have developed a system
for using high-sensitivity FRET-based biosensors to monitor the protease activity of CASP8 and its down-
stream effector, caspase-3, in living single cells. Using this system, we systematically investigated the caspase
cascade by regulating the magnitude of extrinsic signals received by the cell. Furthermore, we determined
the molar concentration of ﬁve caspases and Bid required for hierarchical transmission of apoptotic signals
in a HeLa cell. Based on these quantitative experimental data, we validated a mathematical model suitable
for estimation of the kinetics and dynamics of caspases, which predicts the minimal concentration of
CASP8 required to act as an initiator. Consequently, we found that less than 1% of the total CASP8 proteins
are sufﬁcient to set the apoptotic program in motion if activated. Taken together, our ﬁndings demonstrate
the precise cascade of CASP8-mediated apoptotic signals through the extrinsic pathway.
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Caspases belong to a family of cysteine proteases that speciﬁcally
cleave substrates at sites located after aspartic acid residues in target
amino acid sequences. These proteases play a central role in the apo-
ptotic cell death machinery [1,2]. Caspase-mediated apoptosis follows
two main pathways, intrinsic and extrinsic. The intrinsic pathway
arises from signals that originate within the cell, as a consequence
of cellular stress or DNA damage. The stimulation or inhibition of dif-
ferent Bcl-2 family members results in the leakage of cytochrome c
from mitochondria and the formation of the apoptosome, an assem-
bly composed of cytochrome c, Apaf1 and caspase-9 (CASP9) [3].
The subsequent activation of CASP9 initiates the caspase cascade,
leading to the activation of effector caspases including caspase-3
(CASP3), caspase-6 (CASP6) and caspase-7 (CASP7). On the other
hand, the extrinsic pathway is triggered by stimulation of various
cell surface receptors, called “death receptors”. So far, 6 death recep-
tors have been identiﬁed in mammals [4,5]. Among these, Fas has
been most thoroughly characterized [6–8]. Oligomerization of Fas, ei-
ther by its natural ligand or agonistic anti-Fas antibodies, recruits an
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MORT1), which contains both a death effector domain (DED) and a
death domain, to the cytosolic domain of Fas through homophilic in-
teractions mediated by the death domains. Caspase-8 (CASP8), which
is the inactive form, associates in turn with FADD by interactions be-
tween their DEDmotifs. Within the Fas–FADD–CASP8 complex, called
the death-inducing signaling complex (DISC) [9], CASP8 undergoes
self-cleavage to convert to the active form. Activated CASP8 is re-
leased to the cytosol, and cleaves downstream effector caspases.
Furthermore, it has become apparent that death receptor-mediated
apoptotic signals also activate the intrinsic apoptosis pathway. In
some cells, upon apoptosis induction through the death receptor,
a BH-3-only pro-apoptotic molecule of the Bcl-2 family, BH3-
interacting domain death agonist (Bid), is cleaved by CASP8. Processed
Bid then translocates to mitochondria and stimulates the intrinsic
pathway. Cells that die through the Fas pathway were classiﬁed be-
tween two types: type I, in which the DISC complex can be detected
and CASP8 directly cleaves effector caspases without activation of the
intrinsic pathway; and type II, in which Fas-mediated death relies
mostly on the intrinsic pathway [10–12]. Downstream of CASP8, either
of two signaling pathways can be selected. The recent report suggested
this selectivity depends on the effect of a caspase inhibitor, X-
chromosome linked inhibitor of apoptosis protein (XIAP) [13]. More-
over, CASP8 activation occurs not only in the DISC but also through a
feedback loop derived from the intrinsic apoptotic pathway [14]. The
detailed molecular mechanism has been investigated by the following
reports [15–19]. Those results indicated that CASP8 becomes an active
form via proteolysis by CASP3 and CASP6, which are themselves acti-
vated through the intrinsic pathway [20–22]. However, previous stud-
ies have not yet sufﬁciently explained how the signaling pathways
diverge downstream of CASP8, or why the positive-feedback loop
for CASP8 activation occurs during death receptor-mediated apo-
ptosis. In addition, the recent study suggested that CASP8 activation
requires not only proteolytic processing but also dimerization pro-
cess [23].
Fluorescence resonance energy transfer (FRET) is an effective way
to monitor biological phenomena in living cells [24–27]. For monitor-
ing caspase activation in dying cells, many FRET-based artiﬁcial mol-
ecules have been generated (see review [27]). FRET-based molecules
specialized for tracing of CASP8 activation during apoptosis have also
been generated [28–34]. Monitoring of cells undergoing apoptosis
with FRET-based biosensors enables us not only to show intracellular
events without destroying cells, but also to take accurate measure-
ments of the kinetics and dynamics of enzymatic reactions involving
caspases within single cells.
To deﬁne the kinetics and dynamics of caspases involved in extrin-
sic apoptotic signaling, we used improved FRET-based biosensors and
monitored CASP8 and CASP3 activation following Fas ligation. By reg-
ulating the signal transduction machinery, we also addressed the
selectivity of the signaling pathways downstream of CASP8, and the
physiology of the positive-feedback loop. Based on these experimen-
tal data, we generated a mathematical model, and also conﬁrmed its
validity by experimental tests.
2. Materials and methods
2.1. Regents
Anti-CASP3, anti-CASP9, anti-Bid and anti-PARP antibodies (Cell
Signaling Technology, Danvers, MA), anti-CASP6 (3E8), anti-CASP8
(5F7), anti-CASP10 (4C1) and agonistic anti-human Fas (CH11) [35]
antibodies (MBL, Nagoya, Japan) and anti-actin antibody (MAB1501R,
Chemicon International Inc., Temecula, CA) were commercially
obtained. Carbobenzoyl-IETD-ﬂuoromethylketone (z-IETD-fmk) was
purchased from Peptide Institute Inc. (Minoh, Japan). A synthetic
FK506 analog, AP20187 was a gift from ARIAD Pharmaceuticals(Cambridge, MA). A cocktail of Cy3‐conjugated or non-conjugated
siRNAs (GAAGACAUCAUCCGGAAUA, ACGAUGAGCUGCAGACUGA, GCA
CCUACGUGAGGAGCUU, and CUCCAAAGCUGUUCUGACA) speciﬁc for
human Bid was purchased from Dharmacon Inc. (catalog number:
M-004387-00, Lafayette, CO), and a cocktail of Cy3‐conjugated or
non-conjugated siRNAs (CAGAGAAGUUGGACACCAA, UGUGUGAGAU
GUUGGGAAA, and GGUUUGAUAUGGAGAAACA) speciﬁc for human
CASP6 was purchased from B-Bridge International, Inc. (catalog num-
ber: SHF27A-0698, Sunnyvale, CA). A cocktail of protease inhibitors
was purchased from Nacalai Tesque (Kyoto, Japan).
2.2. Construction of expression vectors
To express FRET-based biosensors SCAT8.1, SCAT8.2 and SCAT3.1
in mammalian cell lines, the DNA fragments were inserted into
the expression vector pCAGGS [36]. To express human ARK5
(AMPK-related protein kinase 5, also known as NUAK1), ARK5 cDNA
was cloned into pIREShyg2 (BD-Clontech, Palo Alto, CA). A
kinase-deﬁcient ARK5 mutant, ARK5(S600A), was generated by re-
placing the serine residue (amino acid 600) in the kinase domain
with alanine by exchange of the PCR-ampliﬁed DNA fragment
containing the mutant sequence. The resulting mutant ARK5(S600A)
cDNA was then inserted into the pIREShyg2 vector. To express fusion
proteins consisting of either the FK506-binding protein 12 variant
(Fv) or the FKBP rapamycin-binding domain of FKBP-associated pro-
tein (FRB) and the protease domain of human CASP8, we obtained
pSH1/HA-Fvls-caspase8 and pSH1/Flag-FRBL-caspase8 [37] from Dr.
J. Wang (Baylor College of Medicine). To ectopically express CASP6
proteins in cells, cDNAs of wild-type CASP6 and two mutants
CASP6CS and CASP6SE were cloned into the expression vector,
pIREShyg2 (BD-Clontech). These CASP6CS and CASP6SE mutants
were replaced the cysteine residue (amino acid 163) with serine in
the active site and the serine residue (amino acid 257) with glutamic
acid in the small subunit by exchange of the PCR-ampliﬁed DNA frag-
ment containing the mutant sequence. To locally express ﬂuorescent
proteins in the plasma membrane and nucleus, we obtained
pCS2-mRFP1-Mem from Dr. N. Ueno (National Institute for Basic Biol-
ogy) and pLBR™-EGFP from Dr. J. Ellenberg (EMBL).
2.3. Cell culture and transfection
The human cervical carcinoma cell line HeLa, the hepatocarcinoma
cell line SKHep-1 and the breast carcinoma cell line MCF-7 were cul-
tured in Dulbecco's Modiﬁed Eagle's medium with 10% fetal calf
serum (FCS). Transfection of plasmid DNAs into adherent cells was
carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For
transfection with siRNAs speciﬁc for human Bid or CASP6, we used
TransFectin™ Lipid Reagent (Bio-Rad Laboratories Inc., Hercules, CA).
2.4. Synthesis of recombinant proteins
For use as standards, we synthesized recombinant proteins,
human CASP3, CASP6, CASP8, CASP9, caspase-10 (CASP10) and Bid
with a cell-free system as previously described [38]. Brieﬂy, cDNAs
encoding protease-deﬁcient CS mutants of CASP3, CASP6, CASP8,
CASP9 and CASP10 were generated by replacing the cysteine residue
in the active site of the protease domain with serine, by exchange of a
PCR-ampliﬁed DNA fragment containing the mutant sequence
followed by cloning into a pEU plasmid. These constructs, and the
pEU construct carrying a cDNA that encodes Bid, were used as a tem-
plate for RNA synthesis; the resulting transcripts were translated
with wheat embryo extracts (WEPRO-1240, CellFree Sciences,
Matsuyama, Japan). Recovery of recombinant proteins was conﬁrmed
by SDS-PAGE and staining with Coomassie Brilliant Blue (Supplemen-
tary Fig. S1). Protein concentration of recombinants was determined
1827K. Kominami et al. / Biochimica et Biophysica Acta 1823 (2012) 1825–1840using the DC Protein Assay kit (Bio-Rad Japan, Tokyo, Japan) and al-
bumin standard solution (PIERCE, Rockford, IL).2.5. Immunoblot analysis
For the detection of full-length and processed forms of CASP8 and
its derivatives, or the conﬁrmation of knock-down effects against Bid
or CASP6 with siRNA, transfectants were incubated in the presence or
absence of apoptotic stimulants for appropriate times, and suspended
in lysis buffer containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
5 mM EDTA, 1% TritonX-100, 0.5% sodium deoxycholate and a cock-
tail of protease inhibitors. Samples were then resolved by SDS-PAGE
and followed by immunoblotting with anti-CASP8, anti-CASP6,
anti-Bid and anti-actin antibodies. In addition, the processing proﬁles
of endogenous CASP8, CASP3 and poly(ADP-ribose) polymerase
(PARP) and exogenous CASP6 derivatives in cells undergoing apopto-
sis were examined by immunoblotting using antibody against each
molecule as well. For the estimation of the number of CASP3, CASP6,
CASP8, CASP9, CASP10 and Bid molecules in a single cell, HeLa cells
were lysed in lysis buffer after counting the number of cells. After
graduated dilution with lysis buffer, samples were resolved by
SDS-PAGE with recombinant proteins, whose quantity has been
predetermined, and followed by immunoblotting with the antibody
against each molecule. After incubation with HRP-conjugated
anti-mouse or anti-rabbit IgG antibodies (Cell Signaling Technology),
immune complexes were visualized with Western Lightning
(PerkinElmer Life Sciences, Inc. Boston, MA).2.6. Bioimaging with ﬂuorescent microscopes
Cells transfected with plasmid constructs or siRNAs were plated in
35-mm glass-bottomed dishes (Asahi Technoglass Co., Tokyo, Japan)
and maintained in growth medium for 1–3 days. Prior to induction
of apoptosis, media was replaced with PBS containing 1 mM CaCl2,
0.5 mM MgCl2 and 10% FCS and then either treated with 200 ng/ml
of agonistic anti-Fas antibody (CH-11) in the presence of 5 μg/ml cy-
cloheximide (CHX) or 100 nM AP20187. During monitoring,
glass-dishes were plated in a heated chamber (MI-IBC, Olympus Co.,
Tokyo, Japan). Fluorescence images were acquired under a ﬂuores-
cent microscope (DMIRE2, Leica Microsystems, Wetzlar, Germany)
equipped with a HCX PL Apo 64×, 1.4 NA oil-immersion objective
(Leica Microsystems), using an interlined charge-coupled device
(CCD) camera (CoolSNAP HQ, Roper Scientiﬁc, Tucson, AZ) controlled
byMetaFluor or MetaMorph software (Universal Imaging, Media, PA).
A D425/40× excitation ﬁlter and D480/40m and HQ535/30m emis-
sion ﬁlters (Chroma Technology Corp. Rockingham, VT), and glass
plate with a refractive index of 0.04 instead of a dichroic mirror, alter-
nated with a ﬁlter changer (MAC5000, Ludl Electronic Products Ltd.,
Hawthorne, NY), was used for the detection of the ﬂuorescence of
super-enhanced cyan ﬂuorescent protein (seCFP) and Venus (a vari-
ant of yellow ﬂorescent protein) [39] and FRET of seCFP→Venus.
To measure volumes of the whole cell and nucleus, image stacks
were acquired on a confocal microscope (LSM710, Carl Zeiss,
Oberkochen, Germany) equipped with a Plan-Apochromat 63×/1.40
Oil DIC M27 objective (Carl Zeiss) and 488 nm and 543 nm laser
lines to excite enhanced green ﬂuorescent protein (EGFP) and mono-
meric red ﬂuorescent protein 1 (mRFP1), respectively. Emission ranges
were selected 492–542 nm for EGFP and 545–702 nm for mRFP1.
The software (ZEN, Carl Zeiss) was used for acquisition of image stacks
and their 3D reconstructions. Both cellular and nuclear regions
were segmented from image stacks using a image processing soft-
ware, VCAT (http://vcad-hpsv.riken.jp/jp/release_software/V-Cat/),
and those volumes were calculated from the segmented regions as
previously described [40].2.7. Treatment of peptide inhibitors
To examine the effects of peptide inhibitors against CASP8 activity,
1 μM z-IETD-fmk was added into the medium 60 min before anti-Fas
antibody treatment, and SCAT8.1- or SCAT3.1-expressing HeLa cells
were monitored for FRET ratio in the presence of the inhibitor.
2.8. Construction of the mathematical model
A mathematical model for apoptotic signal transductions was
constructed based on molecular–biological data (Supplementary Fig.
S2). The network of apoptotic signaling pathways, expressed as a
chemical reaction equation, is summarized in Supplementary Table
S1.
2.8.1. Receptor activation
The apoptotic reaction starts at time zero when a sufﬁciently large
amount of stimulant is present in the culture medium. Natural Fas li-
gand (FasL) or agonistic anti-Fas antibody binds to and induces
trimerization of Fas, following the recruitment of FADD and CASP8,
to form the DISC complex. When sufﬁcient stimulant is present, Fas
ligation on the cell surface is sufﬁciently induced, and DISC formation
is assumed to be constant.
2.8.2. Caspase activation
First, we considered the activation of caspases. All caspases
(CASP3, CASP6, CASP8 and CASP9) are activated by processing of
pro-forms (indicated by C3, C6, C8 and C9) following formation of a
complex. Inactive procaspases bind the upstream activator (indicated
by C*) to form the complex, and are then cleaved to small (S) and
large (L) subunits. These two molecules (S and L) then associate to
form the active caspase complex. This basic mechanism of caspase ac-
tivation can be described as a chemical reaction equation as follows:
Cn þ C↔
ki
kj
CnC
→
km
CnSþ CnLþ C
2CnSþ 2CnL→
km Cn:
Here, the subscript n indicates the caspase-n; and ki, kj, km and kn
indicate the forward and backward reaction rate constants. The
change of the caspase concentration over time is given by the law of
mass action as follows:
d Cn½ 
dt
¼−ki Cn½   C
 þ kj CnC
 
að Þ
d CnC
½ 
dt
¼− kj þ km
 
CnC
  bð Þ
d CnS½ 
dt
¼ d CnL½ 
dt
¼ km CnC
 
−4kn CnS½ 2 CnL½ 2 cð Þ
d Cn½ 
dt
¼ kn CnS½ 2 CnL½ 2: dð Þ
ð1Þ
Interaction between the caspase and its substrate, cleavage of sub-
strate by caspase, and active complex formation of cleaved caspase
are commonly described by Eq. (1).
Next, we considered CASP9 activation through the mitochondria.
Active CASP8 cleaves Bid. A truncated Bid, tBid, translocates into the
mitochondria to change the permeability of the mitochondrial mem-
brane, thereby activating the intrinsic apoptotic pathway. Cyto-
chrome c stored in mitochondria is then released into the
cytoplasm, where it binds APAF-1 to form the apoptosome complex.
Unlike other caspases, which are activated in the cytosol, CASP9 is
multimerized and activated within the apoptosome complex. As
CASP9 activation depends on tBid releasing cytochrome c into the cy-
toplasm, we modeled the CASP9 activation as a nonlinear function of
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sigmoid function of the concentration of tBid.
2.9. Parameter estimation by particle ﬁlter
The parameters and initial conditions estimated based on the results
obtained from our model coincide with the data obtained from in vivo
experiment. We evaluated the correspondence between our model's
predictions and the experimental data using a particle ﬁlter. To generate
the particle ﬁlter, the system was described as a state space model. The
state of the system was indicated by the concentrations of the compo-
nents of the apoptotic signal transduction pathway. The state of the sys-
tem at a certain time point is renewed from the previous time point
according to the model process. The information about the state of the
system throughout the observation process was obtained. Brieﬂy, the
state of the apoptotic signal transduction was estimated based on the
ﬂuorescent intensity obtained from the SCAT indicators.
The particle ﬁlter algorithm can be described as follows: An eval-
uated set of parameters and initial values, designated by θ, was set
for N particles. The state of the system at subsequent time points
was determined according to a model process with system noise.
The observed value, in this case the 535-nm ﬂuorescence from
SCAT8 or SCAT3, was obtained from the model process. We assumed
that the 535-nm ﬂuorescent intensity is proportional to the concen-
tration of SCAT8 or SCAT3. This assumption yields.
535SCAT8 ¼ a1  SCAT8½  þ b1 að Þ
535SCAT3 ¼ a2  SCAT3½  þ b2: bð Þ
ð2Þ
Finally, the likelihood of each particle was tested by the difference
between the ﬂuorescence values obtained from model and the mea-
surement data. The probability that the difference between model
and measurement is normally distributed around mean 0 with vari-
ance σ was obtained.
αn ¼
1ﬃﬃﬃﬃﬃﬃ
2π
p
σ
exp
y nð Þi −Y
 2
2σ2
2
64
3
75: ð3Þ
Here, the observed values obtained from model and the measure-
ment data at a certain time point are designated by yi(n) and Y, respec-
tively. The number of particles was resampled according to the
probability αn. The copy of nth particle was generated depending on
αn. The state of the systemwas calculated from the resampled particle
according to the model process. This operation was iterated until time
point T.
The likelihood of the parameter and initial condition set was cal-
culated from summation of the probability of each particle for all
time points.
loglikelihood ¼
XT
t
∑
i
XN
n
log αnð Þð Þ: ð4Þ
3. Results
3.1. Deﬁnition of caspase activation with FRET-based biosensor
molecules
In our related study, we conﬁrmed that the activation of the initiator
caspase CASP8 occurs in two-step reaction in HeLa cells in response to
extrinsic apoptotic stimuli.3 In the primary phase, small amounts of3 Kominami et al., manuscript (1) in preparation.CASP8 are activated 30 min earlier than a downstream effector caspase,
CASP3; the secondphase occurs after CASP3 activation. This biphasic ac-
tivation of CASP8was observedwhen cells were treatedwith tumor ne-
crosis factor-related apoptosis-inducing ligand (TRAIL) [34,41]. To
deﬁne the kinetics of each caspase throughout the cascade, we used im-
proved FRET-based biosensors, SCAT8.1 and SCAT3.1, which enable
monitoring of the protease activity of CASP8 or CASP3 in single cells
(Fig. 1A). The prototype SCAT8.0, which is a fusion protein consisting
of Venus [39] and seCFP that contains the IETD amino acid sequence
in its linker portion, is suitable for monitoring the activity of CASP8.
We optimized the length of the linker region of SCAT8.0 following the
previously established PCR technique [42]. SCAT8.1,whichwas generat-
ed by deleting 9 amino acids of the C-terminal tail of Venus and adding
an artiﬁcial sequenceGTGGS at the C-terminus of IETD (see Supplemen-
tary Materials and methods), showed the highest efﬁciency of FRET
from seCFP to Venus (Fig. 1A and Supplementary Fig. S3). When
SCAT8.1 was excited at 440 nm in living cells, the emission ratio varied
from 1.7 to 2.8 at maximum level, indicating a high efﬁciency of FRET
compared with the original construct, SCAT8.0. Similarly, SCAT3.1 is a
molecule with high FRET efﬁciency that contains the DEVD sequence
between seCFP and Venus [42]. By using these two improvedmolecules
along with high-throughput techniques, we were able to monitor the
most minute dynamics of caspase activation in single cells, and to
trace the ﬂow of apoptotic signals without destroying cells.
Using SCAT8.1 and SCAT3.1, we examined the dynamics of CASP8
and CASP3 activation in HeLa, SKHep-1 and MCF-7 cells during apo-
ptosis (Fig. 1B–G). In the graph, a decline of the FRET ratio inversely
correlated to an increase in enzymatic activity. In HeLa cells, we
detected the two phases of CASP8 activation as well as the exponen-
tial activation of CASP3 in single cells undergoing apoptosis. These
improved probes clearly showed the high dynamic range of the
FRET ratio, compared with that of FRET-based biosensors used in pre-
vious studies [43]. Similarly, monitoring of the FRET ratio of SCAT8.1
and SCAT3.1 in SKHep-1 cells showed similar kinetics to those in
HeLa cells although the dynamics were accelerated by approximately
1 h (Fig. 1D, E). In contrast, the FRET ratio in MCF-7 cells showed a
distinct pattern from those observed in HeLa and SKHep-1 cells
(Fig. 1F, G). As shown in Fig. 1G, the delayed decline of the FRET
ratio of SCAT3.1 in MCF-7 cells was thought to correlate with the loss
of CASP3 activation because this cell line is genetically deﬁcient in
CASP3 [44]. In the absence of CASP3, it was still detected the dynamics
of the FRET ratio at later hours, suggesting the involvement of another
effector caspase CASP7, which possesses DEVDase activity, in the
processing of SCAT3.1. Alternatively, this DEVDase activity may be
derived from a distinct protease [45]. Notably, we could not detect
signiﬁcant IETDase activity, which would cleave SCAT8.1, within a
normally-occurring time period (i.e.within 5 h in Fig. 1B, D), indicating
that magniﬁed CASP8 activation does not occur in MCF-7 cells during
apoptotic stimulation (Fig. 1F). This data suggests that activated
DEVDase is insufﬁcient to fully activate CASP8 in the second phase in
MCF-7 cells. Thus, using SCAT8.1 and SCAT3.1, we were able to trace
the kinetics and dynamics on the activation of both initiator and effec-
tor caspases in several cell lines.
3.2. Mathematical model for the apoptotic signaling pathways
To present a model that accurately represents the activation
proﬁles of CASP8 and CASP3 in apoptotic cells, we formularized the re-
action processes occurring throughout the caspase cascade in which
CASP8, CASP3, CASP9 and Bid participate as essential components, and
referred to SCAT8.1 and SCAT3.1 instead of the pathway's natural
substrates (Supplementary Fig. S2 and Supplementary Table S1). In
addition, we assumed a positive-feedback loop, passing through the ef-
fector CASP6 and leading to CASP8 activation, and the involvement of
molecules in the regulation of the caspase activity such as caspases-8-
and -10-associated RING proteins (CARPs) [46], in our model.
Fig. 1. Generation andmonitoring of FRET-based biosensors, SCAT8.1 and SCAT3.1. A. The structure of FRET-basedbiosensors, SCAT8.1 andSCAT3.1. SCAT8.1 consists of twoﬂuorescent proteins,
the truncated Venus and full-length seCFP, and contains the CASP8 recognition sequence, IETD, in the linker portion. SCAT3.1 consists of the truncated seCFP and full-length Venus and contains
the CASP3 recognition sequence, DEVD, in the linker portion. B–G. The dynamics of CASP8 and CASP3 activation monitored with either SCAT8.1 or SCAT3.1 in human cell lines. HeLa (B, C),
SKHep-1 (D, E) andMCF-7 (F, G) cells expressing SCAT8.1 or SCAT3.1were treatedwith 200 ng/ml of anti-Fas antibody in the presence of 5 μg/ml CHX andmonitored by FRETduring apoptosis.
Each line in the graph indicates the emission ratio based on the ﬂuorescent intensity of the biosensors detected through the D480/40m (for seCFP) and HQ535/30m (for Venus) emission ﬁlters
in single cells, and is inversely proportional to the CASP8 or CASP3 activity. (n) indicates the number of cells examined. Time zero indicates themomentwhen apoptotic stimulantswere added.
The right panels (B–E) indicate the adjusted proﬁles by converting the moment within an hour based on time courses from single cells (gray lines) and their average (a blue line).
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4 Data not shown.
Fig. 2.Mathematical models of CASP8 and CASP3 activation. A–C. The graphical patterns of CASP8 and CASP3 activation proposed by a model. The numbers of moles of CASP8 and
CASP3 in the model are 100 nM CASP8 and CASP3 (A), 20 nM CASP8 and 100 nM CASP3 (B) and 300 nM CASP8 and 30 nM CASP3 (C), respectively. D. In the case of no intrinsic
apoptotic signaling pathway. Except that there is no linkage through Bid to the mitochondrial pathway, the parameters were set up as indicated in (B). Red and blue lines in each
graph indicate the virtual emission ratio of the FRET-based biosensors after apoptotic stimuli, inversely correlating with a time course on CASP8 and CASP3 activities, respectively.
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molar ratio between initiator and effector caspases in themathematical
model. Because the activation of caspases irreversibly proceeds, the
substrates of caspases including SCAT biosensors are completely
cleaved after sufﬁciently long time has passed from the signal input in
this model. Therefore, it was thought that the transient dynamics of
SCAT biosensor cleavage are affected by the expression level of both ini-
tiator and effector caspases. When CASP8 and CASP3 are present at the
same levels and equally activated, a similar ratio change between SCAT8
and SCAT3 was observed (Fig. 2A). In contrast, when CASP8 is 5-fold
less abundant than CASP3, the graphic data showed a slower decrease
in the ratio change of SCAT8 and a drastic decrease for SCAT3 after pre-
ceding cleavage of SCAT8 (Fig. 2B), indicating proﬁles similar to those in
cells undergoing apoptosis (Fig. 1B–E). If more CASP8 than CASP3 is
present and activated, the ratio change of SCAT8, but not of SCAT3, rap-
idly decreased (Fig. 2C). As a result, SCAT3 cleavage cannot overtake
SCAT8 cleavage. This is signiﬁcantly in discord with the experimental
data. Among three graphical patterns, the graph showing less initiator
caspase than effector caspase agrees with the raw data acquired by
monitoring HeLa cells undergoing apoptosis. Our model suggests that
in HeLa cells the number of CASP3molecules is greater than the number
of CASP8molecules in apoptotic signal transduction. Thus, a model that
postulated lower numbers of CASP8 than CASP3 was more comparable
to the rawdata obtained in HeLa cells, suggesting that initiator caspases
are preservedmuch less than effector caspases in real cell. Alternatively,
the partial activation of CASP8 is enough to transmit apoptotic signals.
3.3. Selectivity of signaling pathways accompanied by CASP8 activation
Next, we modeled the pathway leading to CASP3 activation by
CASP8, either with or without another mitochondria-mediatedpathway. In the mathematic model, the graphical patterns acquired
by setting equal amounts of CASP8 and CASP3 or higher amounts of
CASP8 than CASP3 were not changed if the mitochondrial pathway
existed.4 In contrast, in the situation of lower CASP8 than CASP3,
the ratio change of SCAT3.1 was altered in association with the slow
progression of the reaction (Fig. 2D). By blocking the mitochondria-
mediated apoptotic pathway triggered by Bid, it is possible to experimen-
tally select one pathway, even if two signaling pathways are active in liv-
ing cells. Our mathematical model predicted that the DEVDase activity,
which is detectable by using SCAT3.1, is downregulated but still present
in cellswhosemitochondria-dependent apoptotic signals viadeath recep-
tors are completely shut down.
To validate this model, we attempted to block the mitochondria-
mediated pathway in living cells. Bid is cleaved by active CASP8,
and its processed form translocates into the mitochondria, leading
to the activation of the mitochondrial death pathway [47]. Therefore,
the inactivation of Bid was thought to completely intercept apoptotic
signaling in type II cells such as HeLa. We introduced small interfering
RNA (siRNA) speciﬁc for Bid into HeLa cells, and thereby induced the
downregulation of Bid transcripts by RNA interference. Examination
of the expression level of Bid in transfectants by immunoblot analysis
showed that knockdown was complete. As shown in Fig. 3A,
siRNA-transfected cells showed the downregulation of Bid proteins
after 3 days. In these cells, we monitored the dynamics of CASP8
and CASP3 activation with FRET-based biosensors after treatment
with anti-Fas antibody and CHX (Fig. 3B–E). By setting small spots
on the edges of cells and monitoring their ﬂuorescence, we observed
a rapid drop in ﬂuorescence intensity due to cell shrinkage (Supple-
mentary Fig. S4). This event was utilized to deﬁne “time zero” as
Fig. 3. Effects of the downregulation of Bid in the apoptotic signaling pathway. A. Immunoblot analysis of the downregulation of Bid by RNA interference. HeLa cells were transfected
with either siRNA or Cy3-conjugated siRNA for Bid and incubated for 1–3 days. Cell lysates were prepared at the indicated time and analyzed by SDS-PAGE, followed by immuno-
blotting with an anti-Bid antibody. B, C. The graphical patterns of the CASP8 activation in single cells monitored with SCAT8.1. D, E. The graphical patterns of the CASP3 activation in
the single cells monitored with SCAT3.1. Cy3-positive cells (C, E) and parental cells (B, D), co-expressing either SCAT8.1 or SCAT3.1, were treated with 200 ng/ml of anti-Fas anti-
body and 5 μg/ml of CHX; the emission ratio was monitored. The graphical data were adjusted by converting the moment when cells went away from a scanning spot to time zero.
Representative data from ﬁve independent experiments is shown in each graph.
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to standardize the time schedules of individual cells progressing
through apoptosis, allowing a graphical comparison of caspase activ-
ities. Based on graphic data, we determined that the dynamics of
CASP3 activation are drastically changed, whereas CASP8 activation
does not change in any transfectants, when Bid expression is
downregulated (Fig. 3C, E). These data indicate that in Bid-depleted
cells, CASP3 activation is reduced but still detected and cell shrinkage
has occurred under the circumstances. These results were supported
by a report that CASP3 activation, but not CASP8 activation, is
reduced but detected in Bid-depleted cells when treated with TRAIL
and CHX [34]. Contrary to previous studies showing that the apopto-
tic process through death receptors progresses in a Bid-dependent
manner in type II cells such as HeLa [11,12], apoptosis was observed
in our Bid-depleted cells. In addition, XIAP seems to be functionally
impaired in HeLa cells although it works in type II cells [13]. Taken to-
gether, our results strongly suggest that the direct activation of CASP3
by CASP8 is sustained in HeLa cells although the Bid-dependent
pathway is required for full-activation of CASP3.
3.4. Effects of direct activation of CASP8 in a death receptor-independent
manner
Based on our mathematical model, we hypothesized that pro-
moted activation of CASP8 causes rapid progression of apoptosis
via processing and activating CASP3. To conﬁrm this hypothesis,
we examined CASP8 activation and cell death by inducing artiﬁcial
oligomerization of a chimeric molecule, Fv-CASP8 (FK506-binding
protein containing a F36V mutation, fused with a protease domain
of CASP8) (Fig. 4A) with a synthetic dimerizer, AP20187 [37]. HeLa
cells exogenously expressing Fv-CASP8 were subjected to rapid cell
death by treatment with AP20187. By adding 100 nM AP20187
into the growth medium, transfectants caused to promote celldeath associated with drastic CASP8 activation in less than one
hour and this event is earlier than that of cells treated with
anti-Fas antibody (Fig. 4B). The graphical pattern of CASP8 activa-
tion by a dimerizer showed a rapid and exponential decline of the
FRET ratio compared with that of CASP8 activated through receptor
ligation (Fig. 4C, D). On the other hand, the graphical patterns of
CASP3 activation were not different between cells treated with ei-
ther anti-Fas antibody or AP20187, suggesting similar kinetics
(Fig. 4E, F). In the mathematical model, a 5-fold increase in CASP8
molecules without a corresponding change in CASP3 activation
resulted in the accelerated activation of CASP8 (Fig. 2A, B). Although
the graphical pattern based on experimental data was similar to the
graphical pattern proposed by the mathematical model (Figs. 2A
and 4D), there was a crucial difference between these two patterns.
In the cell, most CASP8 were activated after CASP3 activation
(Fig. 4D, F). To detect the processed form of CASP8, we examined
cell lysates in AP20187-treated cells by immunoblot analysis
(Fig. 4G). By comparison of endogenous CASP8 and exogenous
Fv-CASP8, we found that the exogenous products are 3.6-fold
more abundant than the endogenous products (Fig. 4G, lanes 1
and 2). By treatment with a synthetic dimerizer, the processed
forms of a fusion protein were detected in Fv-CASP8-expressing
cells, but not FRB-CASP8-expressing cells, suggesting in an
inducer-dependent mechanism (Fig. 4G, lanes 8 and 9). As a FKBP
rapamycin-binding (FRB) domain fails to bind with AP20187 [37],
FRB-CASP8 did not work by auto-processing. Interestingly, both
Fv-CASP8 and FRB-CASP8 proteins were mostly processed after
treatment with an anti-Fas antibody, even in the absence of
dimerizer (Fig. 4G, lanes 5 and 6). Although it remains to be clari-
ﬁed if the processed fusion proteins become an active form as de-
scribed [23,48], if nothing else, it was clear this reaction is induced
through a feedback loop in the apoptotic signaling pathways.
These results suggest that the direct activation of CASP8 promotes
5 Data not shown.
Fig. 4. Enhanced CASP8 activation caused the promotion of apoptosis. A. The structure of chimeric Fv-CASP8 and FRB-CASP8 consisting of the artiﬁcial dimerization domain, Fv or
FRB [37] and the protease domain of CASP8. Fv-CASP8, but not FRB-CASP8, is able to dimerize in the presence of the dimerization compound, AP20187. DED, death effector domain.
B. The graphical patterns of CASP8 activation monitored with SCAT8.1. HeLa cells were transfected with either empty vector or plasmid carrying Fv-CASP8 in combination with the
SCAT8.1 gene, incubated for 1 day. Eight single cells expressing Fv-CASP8 were treated with 100 nM AP20187 and six cells carrying empty vector were treated with 200 ng/ml of
anti-Fas antibody and 5 μg/ml of CHX; their emission ratios are each indicated by lines. Time zero indicates the moment when apoptotic stimulants are added. C, D. The graphical
patterns of the CASP8 activation in single cells monitored with SCAT8.1. E, F. The graphical patterns of the CASP3 activation in single cells monitored with SCAT3.1. HeLa cells ex-
pressing Fv-CASP8 were treated with AP20187 (D, F) and HeLa cells carrying empty vector were treated with anti-Fas antibody and CHX (C, E). Graphic data (C–F) were adjusted by
aligning a time schedule of morphological change, and representative data from four or two independent experiments was shown in each graph. G. Immunoblot analysis of CASP8
derivative-expressing cells. HeLa cells were transfected either with plasmids carrying Fv-CASP8 (lanes 2, 5 and 8), FRB-CASP8 (lanes 3, 6 and 9), or control vector (lanes 1, 4 and 7)
and treated with either anti-Fas antibody and CHX for 6 h (lanes 4–6) or AP20187 for 6 h (lanes 7–9). The full-length and processed fragments of endogenous CASP8 and exogenous
derivatives were detected by immunoblotting with an anti-CASP8 antibody.
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Both the quantitative increase and the qualitative change of CASP8
are critical for the progression of apoptosis.
3.5. Effects of partial inactivation of CASP8 in signal transduction
pathways
Tetrapeptide caspase inhibitors are known to speciﬁcally block
processing of substrates by particular caspases: carbobenzoyl-
IETD-ﬂuoromethylketone (z-IETD-fmk) is speciﬁc for active CASP8.
We hypothesized that a low concentration of z-IETD-fmk might affect
CASP8 activation without preventing apoptosis. By pretreatment and
co-incubation with 1 µM z-IETD-fmk in the medium, we examinedSCAT8.1 to monitor the dynamics of CASP8 activation in cells
subjected to apoptotic stimuli by anti-Fas antibody. The data show
that the peptide inhibitor partially suppressed CASP8 activation in
the second phase, because a decline of the FRET ratio was extremely
delayed at this phase (Fig. 5A, B). In contrast, z-IETD-fmk did not in-
hibit CASP3 activity (Fig. 5C, D) or block apoptosis completely.5
These results suggest that a small number of CASP8 molecules are
activated at the primary phase, and are sufﬁcient to activate CASP3.
We reproduced this cellular event in an in vitro system with a recom-
binant protein mixture that included procaspase-3 (proCASP3, an
inactive form), SCAT3.1 and a very small amount of active CASP8.3
Fig. 5. Effects of peptide inhibitors upon CASP8 and CASP3 activation. A, B. The graphical patterns of CASP8 activation monitored with SCAT8.1. C, D. The graphical patterns of CASP3
activation monitored with SCAT3.1. Cells expressing SCAT8.1 (A, B) or SCAT3.1 (C, D) were treated with 200 ng/ml of anti-Fas antibody and 5 μg/ml of CHX in the absence (A, C) or
presence of 1 μM z-IETD-fmk (B, D) in the medium. Representative data from four independent experiments was shown in each graph. E. The graphical patterns of CASP8 and
CASP3 activation proposed by a model. A negative regulator, CARP partially inactivates CASP8 (left panel) but not CASP3 (right panel). Red and blue lines in each graph indicate
the virtual emission ratio of the FRET-based biosensors after apoptotic stimuli.
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itor such as CARP, which negatively regulates CASP8 activation [46]
(Fig. 5E). In the presence of the inhibitor, the emission ratio of
SCAT8 showed a concentration-dependent slow decrease, correlating
to a decline of IETDase activity (Fig. 5E, left panel). In contrast, lines
on the emission ratio of SCAT3 did not change slope in the presence
or absence of inhibitors (Fig. 5E, right panel). The raw data with
HeLa cells matched the graphical pattern obtained without inhibitors,
suggesting that there is no negative regulation of CASP8 activation in
the extrinsic apoptotic pathway. Clearly, this kind of ﬂuctuation of
CASP8 activation, but not CASP3 activation, was predictable by the
mathematical model.
3.6. Involvement of the positive-feedback loop in full activation of CASP8
ARK5 is a serine/threonine protein kinase that belongs to the
AMPK family. It has been reported that ARK5 plays a role as a regula-
tor, suppressing the activity of CASP6 [49]. Therefore, we expected
that the overexpression of ARK5 in cells affects CASP8 activation
through a positive-feedback loop, resulting in a change in the FRET
ratio. For this experiment, we improved SCAT8.1 to generate a third
version (SCAT8.2) with the highest FRET efﬁciency (maximum ratio:
7.0) (Fig. 6A). We introduced ARK5 or a kinase-deﬁcient mutant,
ARK(S600A), with SCAT8.2 into HeLa cells and examined their inhib-
itory effect on CASP6 activity by monitoring CASP8 activation
(Fig. 6B–D). In ARK5-expressing cells, we observed the prolonged
time of CASP8 activation in the second phase, when the dynamics of
the FRET ratio changed sluggishly (Fig. 6C). This data also suggests
that a slow updrift of CASP8 activation results in a delayed occurrence
of cell shrinkage. In contrast, the graphical pattern in cells expressingARK5(S600A) was similar to that of control cells (Fig. 6B, D). These re-
sults suggest that CASP6 is critical for CASP8 activation through the
feedback loop.
To conﬁrm the involvement of CASP6 in CASP8 activation, we ex-
amined whether the upregulation and downregulation of CASP6 pro-
teins by overexpression or RNA interference affect CASP8 activation.
First, we tested the silencing effect of CASP6 expression with siRNA
on CASP8 activation, using FRET-based biosensors. siRNA-transfected
cells showed the downregulation of CASP6 proteins after 3 days
(Fig. 7A). In these cells, we monitored the dynamics of CASP8 and
CASP3 activation with SCAT8.2 and SCAT3.1 after treatment with
anti-Fas antibody and CHX (Fig. 7B–E). Based on graphic data,
we found that it takes longer for siRNA-transfected cells than
untransfected cells to reach a plateau for full activation of CASP8,
suggesting the delayed dynamics of CASP8 activation (Fig. 7B, C). In ad-
dition, cell shrinkage was delayed in siRNA-transfected cells (Fig. 7F),
whereas the CASP3 activation proﬁle was indistinguishable between
siRNA-transfected and untransfected cells (Fig. 7D, E). These results
suggest that the inactivation of CASP6 affects both CASP8 activation
and cell shrinkage, but does not affect CASP3 activation and apoptotic
progression. Furthermore, we also examined the high-dose effect of
CASP6 proteins on CASP8 activation. We generated three plasmid con-
structs encoding wild-type CASP6 or its mutants (Fig. 7G), and
transfected them into HeLa cells. By ectopic expression of wild-type
CASP6, we observed the promotion of the processing of CASP8 when
cells were treated with anti-Fas antibody and CHX (Fig. 7H). In con-
trast, there was no difference on cleavage of endogenous CASP3 and
PARP regardless of expression level of CASP6 (Fig. 7H). When a prote-
ase deﬁcient mutant, CASP6CS, was overexpressed in HeLa cells, the
promotion of the processing of CASP8 was not detected (Fig. 7H).
Fig. 6. Effects of the negative regulator on CASP6 activity. A. The protein structure of the
2nd version of SCAT8.0. The improved construct SCAT8.2 was generated by exchanging
the linker sequence DEVD in SCAT3.1 with IETD. B–D. The graphical patterns of CASP8
activation monitored with SCAT8.2 in single cells undergoing apoptosis. HeLa cells
were transfected with either empty vector (B), plasmid carrying ARK5 cDNA (C) or
kinase-deﬁcient mutant cDNA (D) in combination with the SCAT8.2 gene, and incubat-
ed for 1 day. Transfected cells were treated with 200 ng/ml of anti-Fas antibody and
5 μg/ml of CHX; the emission ratio of SCAT8.2 was monitored. Graphic data were ad-
justed by aligning a time schedule of morphological change, and representative data
from two independent experiments was shown in each graph.
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promotive activity on CASP8 processing even it contains an intact ac-
tive site (Fig. 7G, H). Recently, it has been shown that the phosphoryla-
tion of Ser257 of CASP6 by ARK5 loses its protease activity [50,51].
Clearly, our data conﬁrmed this evidence. Consequently, we conclude
that CASP6 is required for complete activation of CASP8 but not sufﬁ-
cient for execution of apoptosis.
3.7. Validation of the established model
To investigate the reliance on our mathematical model, we tested
the log-likelihood as a function of the initial concentrations of CASP8
and CASP3. We calculated the log-likelihood by using 30 time points
(T=30), two experimental values detected with SCAT8 and SCAT3
(i=2), and 5000 particles (N=5000) for evaluation, by referring to
the previous report [52]. Based on a density plot of the total
log-likelihood, we found that the log-likelihood is maximized when
initial CASP8 and CASP3 concentrations are 110 nM and 190 nM
(Fig. 8A). To conﬁrm whether the result obtained from the model co-
incides with data from experiments, we compared the live imagingdata with SCAT8 and SCAT3 and the deterministic process model
(Fig. 8B). Kinetics of both SCAT8 and SCAT3 processing patterns eval-
uated from the model correspond exactly to those from the live imag-
ing data. Thus, a mathematical model based on comparison with
experimental data is useful for understanding this signaling pathway,
and also for estimating the number of molecules that are involved in
apoptotic signal transduction in single cells.
3.8. Concentration measurement of pro-apoptotic molecules in living
cells
The number of pro-apoptotic molecules necessary to execute
apoptosis in vivo remains unknown. Therefore, we ﬁnally examined
the molar concentration of these proteins in HeLa cells. To determine
the number of CASP3, CASP6, CASP8, CASP9, CASP10 and Bid molecules
in healthy cells, as shown in Supplementary Fig. S1, we used recombi-
nant proteins, generated using a cell-free system [38], as the index of
standardization. We compared the recombinant proteins with cellular
products by immunoblot analyses (Fig. 9A). After calculating the num-
ber of molecules of each of these proteins, we summarized the data
(Table 1). Unexpectedly, we observed that the number of CASP8 mole-
cules is approximately 6 times greater than that of CASP3 in living cells.
Additionally, this number is much higher than the number of CASP8
that has been calculated in the previous study [53]. Next, we measured
the volume of both the whole HeLa cell and its nucleus by monitoring
ﬂuorescent proteins expressed in either plasma membrane or
nucleus, and determining the three-dimensional conformation of the
corresponding compartments (Fig. 9B). We calculated the volume of
these structures and summarized the data (Table 2). As the
whole-cell volume of eight randomly selected cells varied from
5149 μm3 to 9573 μm3, we averaged the volume of eight cells, yielding
a ﬁgure of 6884±1371 μm3. Similarly, by calculating the volume of the
nuclei, we tentatively determined the volume of the cytoplasm to be
5657±1485 μm3. Based on these numerical data, we computed the
concentration of each of these proteins in the cytoplasm: 10.6 μM for
CASP3, 0.9 μM for CASP6, 58.7 μM for CASP8, 0.9 μM for CASP9 and
2.9 μM for Bid. In CASP10, the concentration was lower than 0.4 μM.
CASP10 is a CASP8-homologous molecule and acts as an initiator
caspase in death receptor-mediated cell death. However, the consider-
ably reduced level of CASP10 in HeLa cells seemed to be insufﬁcient to
induce to cell death as reported [54]. In contrast, according to the
mathematical model (Fig. 8B), we predicted the concentration of
CASP8 and CASP3, which are required for hierarchical transmission of
apoptotic signals, to be 110 nM and 190 nM, respectively. Comparing
the experimental to the predicted values, we found that excessive
amounts of CASP8 exist in the cytoplasm. The data indicate that only
1/500th of the CASP8 present in the cytosol is sufﬁcient to initiate
transmission of apoptotic signals.
4. Discussion
In this study, we have established a data-driven and parameter-
optimized mathematical model for extrinsic apoptotic signal transduc-
tion. Our model just pictures the proper reaction and provides novel in-
sights into important regulatory mechanisms for the induction of
apoptosis. Once the signaling pathway is triggered via CASP3 activation
by CASP8, the death process cannot be stopped, even if negative regu-
lators are involved in the pathway. We developed a mathematical
model of this pathway, and veriﬁed it using an experimental approach.
As proposed in the previous report [55], a small amount of active
CASP8 seems to be sufﬁcient to transmit Fas-mediated apoptotic
signals, as long as it is able to get over a threshold for CASP3 activation.
In contrast, we experimentally observed that the delayed
full-activation of CASP8 through a positive-feedback loop inﬂuences
the beginning of cell shrinkage. The quantitative experimental data
predicts the requirement of a factor that regulates cell volume under
Fig. 7. Effects of the downregulation of CASP6 on CASP8 cleavage. A. Immunoblot analysis of the downregulation of CASP6 by RNA interference. HeLa cells were transfected with
either siRNA or Cy3-conjugated siRNA for CASP6 and incubated for 1–3 days. Cell lysates were prepared at the indicated times and analyzed by SDS-PAGE and following immuno-
blotting with an anti-CASP6 antibody. B, C. The graphical patterns of CASP8 activation in single cells monitored with SCAT8.2. D, E. The graphical patterns of the CASP3 activation
monitored with SCAT3.1. Cy3-positive cells (C, E) and parental cells (B, D) were treated with 200 ng/ml of anti-Fas antibody and 5 μg/ml of CHX; the emission ratios of FRET-based
biosensors were monitored. Representative data from two cells in four independent experiments are shown in graphs (B–E). F. The overlay of graphic data shown in (D) and (E),
indicating the time series around cell shrinkage. After vertical extension of the scale, graph D (red) was overlaid on graph E (blue). G. A schematic diagram of constructs. CASP6CS is
a mutant replaced the cysteine residue with serine in the active site of the protease domain. CASP6SE is a mutant replaced the serine residue with glutamic acid. The detail of con-
struction of CASP6 derivatives was described in the Materials and methods. H. Immunoblot analyses of HeLa cells expressing CASP6 derivatives. HeLa cells were transiently
transfected either with plasmids carrying CASP6 (lanes 4–6), CASP6CS (lanes 7–9), CASP6SE (lanes 10–12), or control vector (lanes 1–3) and treated with anti-Fas antibody and
CHX at indicated times. Endogenous CASP8, CASP3, PARP and actin and exogenous CASP6 derivatives were examined by immunoblotting with suitable speciﬁc antibodies. The num-
bers indicate the ratio of full-length CASP8 in each transfectant by calculating the measurements of CASP8 and actin using an image analyzer. Arrows indicate intact proteins while
white arrowheads identify the cleaved fragments.
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by demonstrating that a potassium channel protein, which is a sub-
strate for CASP8, is involved in cell shrinkage.6 Thus, by combining6 Kominami et al., manuscript (2) in preparation.theoretical and experimental approaches, we discovered important
aspects of the caspase cascade and the regulation of death
receptor-mediated apoptosis.
Many mathematical models have been formulated based on data
regarding caspase activation [56–69]. However, it is hard to generate
a realistic mathematical model, because the validation of the model
Fig. 8. Estimations of CASP8 and CASP3 expression using the particle ﬁlter. A. Contour plot of the log-likelihood corresponding to various expression levels of CASP8 and CASP3.
Expression levels of CASP8 and CASP3 required for apoptotic signal transduction were estimated using a particle ﬁlter. The horizontal and vertical axes indicate the expression
level of CASP8 and CASP3, respectively. Bright color and dark color show the area where the log-likelihood is large and small, respectively. The log-likelihood becomes large
when the expression level of CASP3 is greater than that of CASP8. A red dashed line indicates that [CASP3]=0.0209*/[CASP8]. This result supports the claim that our model suc-
cessfully reproduces the dynamics of apoptotic signal transduction when the level of CASP3 is about twice that of CASP8. (*) indicates the best coefﬁcient. B. The comparison be-
tween the results obtained from a deterministic model and the experimental data. The ﬂuorescence indicated by SCAT8 and SCAT3 is plotted as a function of time. Filled rectangles
and circles show the numerical results of our deterministic model when [CASP8]=110 [nM] and [CASP3]=190 [nM], by maximizing log-likelihood. On the other hand, open rect-
angles and circles show the live imaging data of the ﬂuorescence indicated by SCAT8 and SCAT3, respectively. The ﬂuorescence of SCAT biosensors obtained from our model is close
to the experimental data at these levels of CASP8 and CASP3 expression. The data conﬁrm that the expression level of CASP3 is about twice that of CASP8.
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high-sensitivity FRET-based biosensors enabled reciprocal conﬁrma-
tion between predictions based on mathematical models and data
obtained experimentally. One difference between model and obser-
vation was that in experiments, each cell showed an unequal re-
sponse to apoptotic stimuli, resulting in an asynchronous decrease
of the FRET ratio in transfectants (Fig. 1); in contrast, the mathemat-
ical model showed uniform responses to apoptotic stimuli (Fig. 2).
This suggests that the levels of apoptotic signaling molecules may
change throughout the cell cycle. The recent study supported this
possibility [70]. Furthermore, it has been reported that cell-to-cell
variability to apoptotic stimuli is primarily caused by naturally occur-
ring differences in the levels or states of proteins regulating death
receptor-mediated apoptotic signals [71]. To understand the variable
sensitivity of an individual cell to apoptotic stimuli, it will be neces-
sary to perform systematic experiments that allow monitoring of
the whole process of apoptosis within each cell, and to express the
ﬁndings of such experiments in a mathematical model.
Although the drawback of FRET-based biosensors for caspase acti-
vation was thought to be poor sensitivity due to the small dynamic
range of the donor–acceptor pair [43], we developed FRET-based
molecules associated with greatly enhanced sensitivity for the detec-
tion of caspase activation. As a consequence, we experimentally
detected subtle changes of CASP8 activity when a positive-feedback
loop was suppressed (Figs. 6 and 7). In addition, we could measure
a small amount of CASP8 activation even in the presence of peptide
inhibitors (Fig. 5). CASP3 activation was reduced by half, but not
suppressed completely, when the mitochondrial pathway was
blocked (Fig. 3). Clearly, the detection of these events with FRET-
based biosensors was useful for understanding the ﬂow of informa-
tion in apoptotic signal transduction.
Although CASP6 is involved in lamin A cleavage and chromatin con-
densation, it has been suggested that this molecule does not affect in
progression of apoptosis, because no obvious morphological differ-
ences were observed in the apoptotic process between CASP6-
deﬁcient and wild-type cells [72]. However, another report indicated
that the induction of CASP6 expression lowers the cell death threshold
in response to apoptotic signals [73]. Indeed, in this study, the
downregulation of CASP6 caused a delay in full activation of CASP8
and cell shrinkage whereas the upregulation of CASP6 promoted theprocessing of CASP8 (Figs. 6 and 7). Clearly, our results conﬁrm the
established theory that CASP6 processed and activated by CASP3 is
able to cleave CASP8, and the resulting processed form of CASP8 has
protease activity [20,74,75]. This hierarchical reaction process might
be required for a magniﬁcation of apoptotic signals through the cas-
cade but is not essential for the execution of cell death associated
with CASP3 activation. This has been clearly simulated in the previous
study experimentally [65]. In our study, CASP8 activation was ampli-
ﬁed at downstream of CASP6 activation. Nonetheless, although the sec-
ond phase of CASP8 activation (corresponding to the terminal reaction)
should exhibit more exponential ﬂuctuation in the theoretical reaction,
our experimental data showed no enhancement compared with that of
CASP3 activation (Figs. 1 and 7). This observation suggests that there
may be a rate-limiting reaction involved in CASP6 activation in vivo. Ac-
tually, the number of CASP6 proteins was one digit smaller than that of
CASP3 in HeLa cells (Fig. 9A and Table 1). Therefore, CASP6 per se is a
rate-limiting factor for positive-feedback ampliﬁcation of CASP8.
In this study, we used a peptide inhibitor against CASP8 to regu-
late its activity, instead of inhibitor proteins such as ARC, Bap31,
BAR, CARP1 (also termed as hRFI), GMEB1 and MUC1, which have
been reported to associate with and regulate CASP8 [46,76–80]. The
use of low concentrations of peptide inhibitors inhibited CASP8 activ-
ity partially, but did not prevent the execution of apoptosis. This sug-
gests the possibility that high levels of inhibitors would be required
for the complete suppression of CASP8 activation and apoptosis.
Among inhibitor proteins, CARPs have been shown to contribute to
the ubiquitin-mediated proteolysis of CASP8, and to be processed by
CASP3 [46,81]. In our mathematical model, 20 nM CARP1 (i.e., at the
same concentration as CASP8) was insufﬁcient to suppress CASP3 ac-
tivation and apoptosis, although it was able to partially downregulate
the activity of CASP8 (Fig. 5E). Although inhibitor proteins, including
CARP1 inhibited CASP8 activation when they were overexpressed
[46], it has not been determined whether endogenous molecules sup-
press CASP8 activation. Another type of caspase inhibitor other than
CARP such as c-FLIP is reported [82]. Therefore, we investigated the
inhibitory effect by different manner from CARP on the transient dy-
namics of SCAT cleavage. CARP inhibits CASP8 by directly binding to
CASP8, whereas c-FLIP intercurrently acts on the interaction between
DISC and CASP8. By modifying our model in the interaction between
DISC and CASP8, we observed that the c-FLIP-type inhibitor
Fig. 9. Quantitative analyses of molecules involved in apoptotic signal transduction. A. Immunoblot analyses for estimating the amount of caspases and Bid in HeLa cells. Protein
content of caspases (CASP3, CASP6, CASP8, CASP9 and CASP10) and Bid in extracts of precounted HeLa cells was determined by SDS-PAGE followed by immunoblotting with suit-
able speciﬁc antibodies. Recombinant proteins were used, in the indicated quantities, as the index of standardization. B. Estimation of the volume of the cell body and nucleus of
HeLa cells. Eight HeLa cells expressing both plasma membrane-bound mRFP1 and nuclear LBR-EGFP were imaged under a confocal microscope (left panels). The three-dimensional
ﬂuorescent conformations of the cells and nuclei were constructed as described in the Materials and methods (right panels).
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Table 1
The number of caspase and Bid proteins in a single cell.
Protein Total length (amino acids) Molecular weight (g) Number (per cell)
CASP3 277 31,593.8 3.6×107
CASP6 293 33,309.9 3.2×106
CASP8 481 55,707.6 2.0×108
CASP9 416 46,280.8 2.9×106
CASP10 522 58,977.5 b1.4×106
Bid 195 21,994.6 9.9×106
Table 2
The volume of the whole-cell and nucleus of HeLa cells.
Cell number Volume (μm3)
Whole-cell (a) Nucleus (b) Cytoplasm (a–b)
#1 6098 1307 4791
#2 9573 1090 8483
#3 5149 1508 3641
#4 6292 1205 5087
#5 6019 1154 4865
#6 7849 900 6949
#7 6715 1053 5662
#8 7374 1602 5772
Mean±SD 6884±1371 1227±235 5656±1485
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ates SCAT8 cleavage as well as CARP.7 This indicates that the rapid
cleavage of SCAT3 after the preceding slow SCAT8 cleavage, as
shown in Fig. 5E, is reproduced to decrease the effective concentra-
tion of CASP8 independently on the inhibition manner. Such determi-
nations will require further studies of the function of these inhibitors
in vivo.
Finally, we focused on how apoptotic signals via CASP8 activation
are transmitted within cells. Our study indicated that if ~0.2% of the
total CASP8 proteins are locally activated in HeLa cells, they would
be sufﬁcient to initiate transmission of apoptotic signals in the extrin-
sic pathway. Recently, it has been proposed that only 30 CASP8 mol-
ecules are enough to activate the apoptotic cascade if the positive
feedback ampliﬁcation loop exists [83]. In case that CASP8 is used in
this way, it provides an efﬁcient system to draw on the apoptotic
process in a cell. However, in healthy cells, survival factors or growth
factors are thought to negatively affect apoptotic signals [84]. It may
reduce the transmission efﬁciency of CASP8 under such a condition.
Since the extrinsic apoptotic pathwaywas established in the ancestral
vertebrate during evolution [85], and CASP8 exists in a wide variety of
invertebrates,8 it is thought that CASP8 is not speciﬁc to death
receptor-mediated apoptosis. It is likely that the majority of “extra”
CASP8 molecules in the cell play various physiological roles, as
suggested in previous reports [86–88].
In summary, we developed a detection system that uses
high-sensitivity FRET-based biosensors to monitor the dynamics of
caspase activation in the highest possible detail. With this system,
we were able to visualize the progress of CASP8 and CASP3 activation
at the single-cell level, leading to the correct identiﬁcation of the
magnitude and rate of apoptotic signals in the pathway. Furthermore,
by expressing our results as a mathematical model, we were able to
determine the precise cascade of the CASP8-mediated signaling.
Thus, our systematic study has enabled us to reconstruct the ﬂows
of apoptotic signals, thereby allowing visualization and simulation
of molecular dynamics.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.07.003.7 Sakamaki et al., unpublished data.
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